Open Questions

This page preserves unresolved scientific and organizational questions.

Scientific Questions

In IMMUNE HIERARCHY, how much of the altered adaptive immune outcome is driven by antigen abundance versus the source and context of antigen acquisition?
Do replication-defective or miRNA-silenced influenza constructs promote broader APC sampling from intact virions rather than infected-cell debris?
Why does PA targeting not produce the expected dominant CD8 shift if the canonical NP/PA hierarchy predicts a stronger PA-dependent effect?
Is the major CD8 difference in the immune-hierarchy project primarily NP-associated, and what does that imply about peptide presentation and antigen capture?
In ADAR LICENSING, does vertebrate RNAi machinery act mainly as an ADAR1 licensing layer during infection rather than as a canonical antiviral RNAi system?
Which RNA-binding proteins beyond AGO2/RISC and DROSHA/DGCR8 influence ADAR1 substrate selection?
Which respiratory vector platform has the best balance of payload capacity, tropism, manufacturability, immunogenicity, and redosing potential?

Which person owns each project-family page?
Which datasets support each major claim?
Which project pages are manuscript-stage versus concept-stage?
Which methods are mature enough to serve as lab standards?
Which negative results or abandoned ideas should be documented before they are lost?